nodes	percent_of_prediction	percent_of_DWPC	metapath
Mepivacaine—Cranial nerve paralysis—Vincristine—lymphatic system cancer	0.11	0.11	CcSEcCtD
Mepivacaine—Cranial nerve paralysis—Methotrexate—lymphatic system cancer	0.0535	0.0535	CcSEcCtD
Mepivacaine—Meningism—Methotrexate—lymphatic system cancer	0.0356	0.0356	CcSEcCtD
Mepivacaine—Meningitis—Carmustine—lymphatic system cancer	0.0344	0.0344	CcSEcCtD
Mepivacaine—Paralysis—Vincristine—lymphatic system cancer	0.0183	0.0183	CcSEcCtD
Mepivacaine—Tinnitus—Mechlorethamine—lymphatic system cancer	0.015	0.015	CcSEcCtD
Mepivacaine—Urinary incontinence—Carmustine—lymphatic system cancer	0.0129	0.0129	CcSEcCtD
Mepivacaine—Sweating increased—Fludarabine—lymphatic system cancer	0.0127	0.0127	CcSEcCtD
Mepivacaine—Sweating—Teniposide—lymphatic system cancer	0.0127	0.0127	CcSEcCtD
Mepivacaine—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.0115	0.0115	CcSEcCtD
Mepivacaine—Swelling—Carmustine—lymphatic system cancer	0.011	0.011	CcSEcCtD
Mepivacaine—Chills—Teniposide—lymphatic system cancer	0.0107	0.0107	CcSEcCtD
Mepivacaine—Swelling—Mitoxantrone—lymphatic system cancer	0.0102	0.0102	CcSEcCtD
Mepivacaine—Agitation—Teniposide—lymphatic system cancer	0.00951	0.00951	CcSEcCtD
Mepivacaine—Chills—Fludarabine—lymphatic system cancer	0.00938	0.00938	CcSEcCtD
Mepivacaine—Anaphylactoid reaction—Mitoxantrone—lymphatic system cancer	0.00929	0.00929	CcSEcCtD
Mepivacaine—Hypertension—Teniposide—lymphatic system cancer	0.00894	0.00894	CcSEcCtD
Mepivacaine—Paralysis—Methotrexate—lymphatic system cancer	0.00888	0.00888	CcSEcCtD
Mepivacaine—Urinary retention—Vincristine—lymphatic system cancer	0.00878	0.00878	CcSEcCtD
Mepivacaine—Cardiac arrest—Vincristine—lymphatic system cancer	0.00878	0.00878	CcSEcCtD
Mepivacaine—Oedema—Teniposide—lymphatic system cancer	0.00845	0.00845	CcSEcCtD
Mepivacaine—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00844	0.00844	CcSEcCtD
Mepivacaine—Agitation—Fludarabine—lymphatic system cancer	0.00836	0.00836	CcSEcCtD
Mepivacaine—Tachycardia—Teniposide—lymphatic system cancer	0.00825	0.00825	CcSEcCtD
Mepivacaine—Hyperhidrosis—Teniposide—lymphatic system cancer	0.00817	0.00817	CcSEcCtD
Mepivacaine—Pruritus—Mechlorethamine—lymphatic system cancer	0.00811	0.00811	CcSEcCtD
Mepivacaine—Hypotension—Teniposide—lymphatic system cancer	0.0079	0.0079	CcSEcCtD
Mepivacaine—Convulsion—Fludarabine—lymphatic system cancer	0.00788	0.00788	CcSEcCtD
Mepivacaine—Sweating increased—Mitoxantrone—lymphatic system cancer	0.00757	0.00757	CcSEcCtD
Mepivacaine—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00743	0.00743	CcSEcCtD
Mepivacaine—Oedema—Fludarabine—lymphatic system cancer	0.00743	0.00743	CcSEcCtD
Mepivacaine—Vomiting—Mechlorethamine—lymphatic system cancer	0.00729	0.00729	CcSEcCtD
Mepivacaine—Apnoea—Methotrexate—lymphatic system cancer	0.00728	0.00728	CcSEcCtD
Mepivacaine—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00718	0.00718	CcSEcCtD
Mepivacaine—Drowsiness—Mitoxantrone—lymphatic system cancer	0.00693	0.00693	CcSEcCtD
Mepivacaine—Chills—Bleomycin—lymphatic system cancer	0.00688	0.00688	CcSEcCtD
Mepivacaine—Sweating—Vincristine—lymphatic system cancer	0.00682	0.00682	CcSEcCtD
Mepivacaine—Nausea—Mechlorethamine—lymphatic system cancer	0.00681	0.00681	CcSEcCtD
Mepivacaine—Urticaria—Teniposide—lymphatic system cancer	0.00671	0.00671	CcSEcCtD
Mepivacaine—Body temperature increased—Teniposide—lymphatic system cancer	0.00668	0.00668	CcSEcCtD
Mepivacaine—Erythema—Bleomycin—lymphatic system cancer	0.00667	0.00667	CcSEcCtD
Mepivacaine—Paraesthesia—Fludarabine—lymphatic system cancer	0.00667	0.00667	CcSEcCtD
Mepivacaine—Sweating—Mitoxantrone—lymphatic system cancer	0.00664	0.00664	CcSEcCtD
Mepivacaine—Bradycardia—Mitoxantrone—lymphatic system cancer	0.00633	0.00633	CcSEcCtD
Mepivacaine—Hypersensitivity—Teniposide—lymphatic system cancer	0.00622	0.00622	CcSEcCtD
Mepivacaine—Asthenia—Teniposide—lymphatic system cancer	0.00606	0.00606	CcSEcCtD
Mepivacaine—Pruritus—Teniposide—lymphatic system cancer	0.00598	0.00598	CcSEcCtD
Mepivacaine—Body temperature increased—Fludarabine—lymphatic system cancer	0.00587	0.00587	CcSEcCtD
Mepivacaine—Erythema—Carmustine—lymphatic system cancer	0.00582	0.00582	CcSEcCtD
Mepivacaine—Back pain—Carmustine—lymphatic system cancer	0.00563	0.00563	CcSEcCtD
Mepivacaine—Chills—Mitoxantrone—lymphatic system cancer	0.00558	0.00558	CcSEcCtD
Mepivacaine—Vision blurred—Carmustine—lymphatic system cancer	0.00549	0.00549	CcSEcCtD
Mepivacaine—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00547	0.00547	CcSEcCtD
Mepivacaine—Tremor—Carmustine—lymphatic system cancer	0.00546	0.00546	CcSEcCtD
Mepivacaine—Oedema—Bleomycin—lymphatic system cancer	0.00544	0.00544	CcSEcCtD
Mepivacaine—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00544	0.00544	CcSEcCtD
Mepivacaine—Erythema—Mitoxantrone—lymphatic system cancer	0.00541	0.00541	CcSEcCtD
Mepivacaine—Back pain—Vincristine—lymphatic system cancer	0.00538	0.00538	CcSEcCtD
Mepivacaine—Vomiting—Teniposide—lymphatic system cancer	0.00537	0.00537	CcSEcCtD
Mepivacaine—Agitation—Carmustine—lymphatic system cancer	0.00535	0.00535	CcSEcCtD
Mepivacaine—Asthenia—Fludarabine—lymphatic system cancer	0.00533	0.00533	CcSEcCtD
Mepivacaine—Headache—Teniposide—lymphatic system cancer	0.00529	0.00529	CcSEcCtD
Mepivacaine—Pruritus—Fludarabine—lymphatic system cancer	0.00525	0.00525	CcSEcCtD
Mepivacaine—Back pain—Mitoxantrone—lymphatic system cancer	0.00524	0.00524	CcSEcCtD
Mepivacaine—Agitation—Vincristine—lymphatic system cancer	0.00511	0.00511	CcSEcCtD
Mepivacaine—Vision blurred—Mitoxantrone—lymphatic system cancer	0.0051	0.0051	CcSEcCtD
Mepivacaine—Hypotension—Bleomycin—lymphatic system cancer	0.00509	0.00509	CcSEcCtD
Mepivacaine—Convulsion—Carmustine—lymphatic system cancer	0.00505	0.00505	CcSEcCtD
Mepivacaine—Hypertension—Carmustine—lymphatic system cancer	0.00503	0.00503	CcSEcCtD
Mepivacaine—Nausea—Teniposide—lymphatic system cancer	0.00502	0.00502	CcSEcCtD
Mepivacaine—Anxiety—Carmustine—lymphatic system cancer	0.00494	0.00494	CcSEcCtD
Mepivacaine—Paraesthesia—Bleomycin—lymphatic system cancer	0.00489	0.00489	CcSEcCtD
Mepivacaine—Convulsion—Vincristine—lymphatic system cancer	0.00482	0.00482	CcSEcCtD
Mepivacaine—Hypertension—Vincristine—lymphatic system cancer	0.0048	0.0048	CcSEcCtD
Mepivacaine—Oedema—Carmustine—lymphatic system cancer	0.00475	0.00475	CcSEcCtD
Mepivacaine—Vomiting—Fludarabine—lymphatic system cancer	0.00472	0.00472	CcSEcCtD
Mepivacaine—Convulsion—Mitoxantrone—lymphatic system cancer	0.00469	0.00469	CcSEcCtD
Mepivacaine—Hypertension—Mitoxantrone—lymphatic system cancer	0.00467	0.00467	CcSEcCtD
Mepivacaine—Headache—Fludarabine—lymphatic system cancer	0.00465	0.00465	CcSEcCtD
Mepivacaine—Tachycardia—Carmustine—lymphatic system cancer	0.00464	0.00464	CcSEcCtD
Mepivacaine—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.00463	0.00463	CcSEcCtD
Mepivacaine—Anxiety—Mitoxantrone—lymphatic system cancer	0.00459	0.00459	CcSEcCtD
Mepivacaine—Oedema—Vincristine—lymphatic system cancer	0.00454	0.00454	CcSEcCtD
Mepivacaine—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00454	0.00454	CcSEcCtD
Mepivacaine—Hypotension—Carmustine—lymphatic system cancer	0.00444	0.00444	CcSEcCtD
Mepivacaine—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00442	0.00442	CcSEcCtD
Mepivacaine—Oedema—Mitoxantrone—lymphatic system cancer	0.00442	0.00442	CcSEcCtD
Mepivacaine—Nausea—Fludarabine—lymphatic system cancer	0.00441	0.00441	CcSEcCtD
Mepivacaine—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00439	0.00439	CcSEcCtD
Mepivacaine—Shock—Mitoxantrone—lymphatic system cancer	0.00435	0.00435	CcSEcCtD
Mepivacaine—Urticaria—Bleomycin—lymphatic system cancer	0.00433	0.00433	CcSEcCtD
Mepivacaine—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00431	0.00431	CcSEcCtD
Mepivacaine—Body temperature increased—Bleomycin—lymphatic system cancer	0.0043	0.0043	CcSEcCtD
Mepivacaine—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00427	0.00427	CcSEcCtD
Mepivacaine—Paraesthesia—Carmustine—lymphatic system cancer	0.00427	0.00427	CcSEcCtD
Mepivacaine—Hypotension—Vincristine—lymphatic system cancer	0.00424	0.00424	CcSEcCtD
Mepivacaine—Somnolence—Carmustine—lymphatic system cancer	0.00422	0.00422	CcSEcCtD
Mepivacaine—Hypotension—Mitoxantrone—lymphatic system cancer	0.00413	0.00413	CcSEcCtD
Mepivacaine—Paraesthesia—Vincristine—lymphatic system cancer	0.00407	0.00407	CcSEcCtD
Mepivacaine—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00401	0.00401	CcSEcCtD
Mepivacaine—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00397	0.00397	CcSEcCtD
Mepivacaine—Somnolence—Mitoxantrone—lymphatic system cancer	0.00393	0.00393	CcSEcCtD
Mepivacaine—Asthenia—Bleomycin—lymphatic system cancer	0.00391	0.00391	CcSEcCtD
Mepivacaine—Pruritus—Bleomycin—lymphatic system cancer	0.00385	0.00385	CcSEcCtD
Mepivacaine—Body temperature increased—Carmustine—lymphatic system cancer	0.00376	0.00376	CcSEcCtD
Mepivacaine—Body temperature increased—Vincristine—lymphatic system cancer	0.00359	0.00359	CcSEcCtD
Mepivacaine—Urticaria—Mitoxantrone—lymphatic system cancer	0.00351	0.00351	CcSEcCtD
Mepivacaine—Hypersensitivity—Carmustine—lymphatic system cancer	0.0035	0.0035	CcSEcCtD
Mepivacaine—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00349	0.00349	CcSEcCtD
Mepivacaine—Vomiting—Bleomycin—lymphatic system cancer	0.00346	0.00346	CcSEcCtD
Mepivacaine—Drowsiness—Methotrexate—lymphatic system cancer	0.00345	0.00345	CcSEcCtD
Mepivacaine—Asthenia—Carmustine—lymphatic system cancer	0.00341	0.00341	CcSEcCtD
Mepivacaine—Hypersensitivity—Vincristine—lymphatic system cancer	0.00334	0.00334	CcSEcCtD
Mepivacaine—Sweating—Methotrexate—lymphatic system cancer	0.00331	0.00331	CcSEcCtD
Mepivacaine—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00326	0.00326	CcSEcCtD
Mepivacaine—Asthenia—Vincristine—lymphatic system cancer	0.00325	0.00325	CcSEcCtD
Mepivacaine—Nausea—Bleomycin—lymphatic system cancer	0.00323	0.00323	CcSEcCtD
Mepivacaine—Asthenia—Mitoxantrone—lymphatic system cancer	0.00317	0.00317	CcSEcCtD
Mepivacaine—Dizziness—Carmustine—lymphatic system cancer	0.00314	0.00314	CcSEcCtD
Mepivacaine—Vomiting—Carmustine—lymphatic system cancer	0.00302	0.00302	CcSEcCtD
Mepivacaine—Dizziness—Vincristine—lymphatic system cancer	0.003	0.003	CcSEcCtD
Mepivacaine—Headache—Carmustine—lymphatic system cancer	0.00298	0.00298	CcSEcCtD
Mepivacaine—Tinnitus—Methotrexate—lymphatic system cancer	0.00289	0.00289	CcSEcCtD
Mepivacaine—Vomiting—Vincristine—lymphatic system cancer	0.00288	0.00288	CcSEcCtD
Mepivacaine—Headache—Vincristine—lymphatic system cancer	0.00284	0.00284	CcSEcCtD
Mepivacaine—Nausea—Carmustine—lymphatic system cancer	0.00282	0.00282	CcSEcCtD
Mepivacaine—Vomiting—Mitoxantrone—lymphatic system cancer	0.00281	0.00281	CcSEcCtD
Mepivacaine—Chills—Methotrexate—lymphatic system cancer	0.00278	0.00278	CcSEcCtD
Mepivacaine—Headache—Mitoxantrone—lymphatic system cancer	0.00277	0.00277	CcSEcCtD
Mepivacaine—Erythema—Methotrexate—lymphatic system cancer	0.0027	0.0027	CcSEcCtD
Mepivacaine—Nausea—Vincristine—lymphatic system cancer	0.00269	0.00269	CcSEcCtD
Mepivacaine—Nausea—Mitoxantrone—lymphatic system cancer	0.00262	0.00262	CcSEcCtD
Mepivacaine—Back pain—Methotrexate—lymphatic system cancer	0.00261	0.00261	CcSEcCtD
Mepivacaine—Vision blurred—Methotrexate—lymphatic system cancer	0.00254	0.00254	CcSEcCtD
Mepivacaine—Convulsion—Methotrexate—lymphatic system cancer	0.00234	0.00234	CcSEcCtD
Mepivacaine—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.0022	0.0022	CcSEcCtD
Mepivacaine—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.00213	0.00213	CcSEcCtD
Mepivacaine—Hypotension—Methotrexate—lymphatic system cancer	0.00206	0.00206	CcSEcCtD
Mepivacaine—Paraesthesia—Methotrexate—lymphatic system cancer	0.00198	0.00198	CcSEcCtD
Mepivacaine—Somnolence—Methotrexate—lymphatic system cancer	0.00196	0.00196	CcSEcCtD
Mepivacaine—Urticaria—Methotrexate—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Mepivacaine—Body temperature increased—Methotrexate—lymphatic system cancer	0.00174	0.00174	CcSEcCtD
Mepivacaine—Hypersensitivity—Methotrexate—lymphatic system cancer	0.00162	0.00162	CcSEcCtD
Mepivacaine—Asthenia—Methotrexate—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Mepivacaine—Pruritus—Methotrexate—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Mepivacaine—Dizziness—Methotrexate—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Mepivacaine—Vomiting—Methotrexate—lymphatic system cancer	0.0014	0.0014	CcSEcCtD
Mepivacaine—Headache—Methotrexate—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Mepivacaine—Nausea—Methotrexate—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
